Bukwang Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 12, 2021 at 08:00 am
Share
Bukwang Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 47,824.72 million compared to KRW 40,349.84 million a year ago. Net income was KRW 657.42 million compared to net loss of KRW 6,156.85 million a year ago. Basic earnings per share from continuing operations was KRW 10 compared to basic loss per share from continuing operations of KRW 90.9091 a year ago. Diluted earnings per share from continuing operations was KRW 10 compared to diluted loss per share from continuing operations of KRW 90.9091 a year ago. Basic earnings per share was KRW 10 compared to basic loss per share of KRW 100 a year ago.
For the nine months, sales was KRW 128,546.34 million compared to KRW 120,194.16 million a year ago. Net loss was KRW 2,825.56 million compared to KRW 5,648.59 million a year ago. Basic loss per share from continuing operations was KRW 41 compared to KRW 81.8182 a year ago. Diluted loss per share from continuing operations was KRW 41 compared to KRW 81.8182 a year ago. Basic loss per share was KRW 41 compared to KRW 90 a year ago.
Bukwang Pharm Co Ltd is a Korea-based company principally engaged in the manufacture and sale of pharmaceutical products. The Company operates its business through two segments. The Medicines and Quasi-drugs segment mainly produces and distributes pharmaceutical products including antidiabetic agents, anemic medicines, thyroid parathyroid hormone drugs, antihistamines, epileptic drugs, bronchodilators, stomatitis drugs, anti-malignant tumors, gum nutrition, hepatitis treatments, targeted anticancer agents, and others. The Research and Development segment mainly researches and develops pharmaceutical products.